haemophilia Flashcards

1
Q

product of coagulation cascade that allows secondary haemostasis

A

yields thrombin which converts fibrinogen to fibrin
- stabilises clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

fibrinolytic system

A

breaks down fibrinogen + fibrin
- activation of fibrinolytic system generates plasmin (in presence of thrombin) which is responsible for the lysis of fibrin clots

breakdown of fibrinogen + fibrin results in polypeptides results in polypeptides = fibrin degradation products = DDimer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

how is fibrin converted to fibrin degradation products (DDimers)

A

by plasmin!

plasminogen –(tissue plasminogen activator)-> plasmin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

disseminated intravascular coagulation (DIC)

A

excessive + inappropriate activation of haemostatic system (primary, secondary + fibrinolysis)

microvascular thrombus formation - end organ failure
clotting factor consumptom -> bruising purpura + generalised bleeding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

pathophysio of DIC

A

process of coagulation + fibrinolysis are dysregulated -> result is widespreaf clotting with resultant bleeding

critical mediator of DIC = tissue factor (TF) - exposed to circulation after vascular damage

on activation, TF binds with coagulation factors that then triggers the extrinsic pathway (via factor VII) which subsequently triggers the intrinsic pathway (XIItoXItoIX)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

causes of DIC

A

sepsis
trauma
obstetric emergencies - elevated LFTs, low platelets (HELLP)
malignancy - eats through tissue, slower process

hypovolaemic shock

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

investigation findings of DIC

A

low platelets
low fibrinogen
HIGH fibrinogen degradation products (DDimers)
high PT + APTT

schistocytes due to microangiopathic haemolytic anaemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

management of DIC

A

treat underlying cause
replacement therapy
- platelet transfusions
- plasma transfusions
- fibrongen replacement

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

prothrombin time, APTT, bleeding time + platelet count in warfarin administration

A

prothrombin time - prolonged
APTT - normal
bleeding time - normal
platelet count in - normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

prothrombin time, APTT, bleeding time + platelet count in aspirin administration

A

prothrombin time - normal
APTT - normal
bleeding time - PROLONGED
platelet count in - normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

prothrombin time, APTT, bleeding time + platelet count in heparin admin

A

prothrombin time - normal/maybe prolonged
APTT - prolonged
bleeding time - normal
platelet count - normal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

prothrombin time, APTT, bleeding time + platelet count in DIC

A

prolonged - prothrombin time, APTT, bleeding time

LOW - platelet count

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

haemophilia

A

hereditary disorder in which abnormally prolonged bleeding recurs episodically
- no abnormaliry of primary haemostasis

x-linked recessive - 30% have NO fam history

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

types of haemophilia

A

haemophilia A (factor VIII def) - commonest

haemophilia B ( factor IX deficiency)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

haemophilia features

A

recurrent haemarthroses (bleeds in joints)
- iron in these spots fuel neovascularisation - more blood vessels -> more prone to bleeds

recurrent soft tissue bleeds - bruising in toddlers
prolonged bleeding after denta extractions, surgery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

investigation findings in haemophilia

A

prolonged APPT
normal bleeding time, thrombin time, prothrombin time

17
Q

arterial thrombosis

A

high pressure system
atherosclerosis
platelet rich thrombus

Mx = aspirin + other anti-platelet drugs
- modify atherosclerosis risk factors

18
Q

venous thrombosis

A

lower pressure system
virchows triad -> stasis, endothelial damage, hypercoagulability

platelets not activated
activates coagulation cascade - rich in fibrin clot

Mx = heparin/warfarin/new oral anticoags

19
Q

extrinsic pathway

A

Tissue Factor (TF, factor III) activates VII to VIIa

VIIa activates X to Xa

20
Q

common pathway

A

Xa + Va (prothrombinase complex) facilitates conversion of prothrombin (factor II) to thrombin

thrombin facilitates the conversion of fibrinogen (factor I) to fibrin (factor XIII, makes stable)

21
Q

intrinsic pathway

A

sub endothelial collagen (SEC) exposed in vessel injury converts XII to XIIa which converts XI -> XIa which converts IX -> IXa

–> VIIIa + vWF activates conversion of X -> Xa

22
Q

what inhibits the intrinsic pathway

23
Q

how is the intrinsic pathway measured

24
Q

what initially activates the intrinsic pathway

A

subendothelial collagen (SEC)

25
what inhibits the extrinsic pathway
warfarin
26
how is extrinisc pathway measured
prothrombin time (extrinsic activated by tissue factor)
27
immune/idiopathic thrombocytopenic purpura (ITP)
an immune mediated reduction in platelet count - antibodies are directed against the glycoprotein IIb/IIIa or Ib-V-IV kids = usually have an acute thrombocytopenia that may follow infection or vaccination adults = more chronic condition
28
ITP in kids
self limiting disease following viral infection/vaccination bruising, petechial/purpuric rash bleeding less common, typically present as epistaxis or gingival bleeding no Mx - resolves in 80% within 6 months - avoid activities involving trauma
29
ITP in adults
chronic relapsing disease - 85% spontaneously remit in 3-6months commoner in older females maybe detected incidentally following routine bloods symptomatic - petechia, purpura, bleeding (epistaxis) Ix - isolated thrombocytopenia, diagnosis of exclusion
30
management of ITP in adults
oral prednisolone pooled normal human immunoglobin (IVIG) may also be used - raises platelet count quicker than steroids, therefore may be used if active bleeding or an urgent invasive procedure required
31
Evans syndrome
ITP assoc with autoimmune haemolytic anaemia (AIHA)
32
thrombotic thrombocytopenic purpura (TTP)
abnormally cleaved von Willebrand factor (due to abnormal ADAMST13) leading to platelt aggregation, thrombus formation + systemic microangiopathu rare, typically adult females hereditary - congenital mutation of ADAMST13 autoimmune - AI inhibition of ADAMST13
33
pathophysio of TTP
abnormally large + sticky multimers of von Willebrands factor cause platelets to clump in vessels in TTP there is a deficiency of ADAMST13 which breaks down (cleaves) large multimers of vWF (overlaps with haemolytic uraemic syndrome)
34
features of thrombotic thrombocytopenic purpura(TTP)
fever microangiopathic haemolytic anaemia (MAHA) thrombocytopenic purpura CNS involvement - headache, confusion, seizures AKI/renal failure
35
TTP investigations
urine dip - haematuria + proteinuria (non-nephrotic range) FBC - normocytic anaemia, thrombocytopenia, raised neutrophils U&E - raised urea + creatinine clotting normal blood film - reticulocytosis (2nd to haemolysis) + schistocytes LFT, LDH, DDimers raised + haptoglobins low - consistent with haemolysis DIAGNOSIS = low ADAMST13 activity
36
management of TTP
plasma exchange started within 24hrs of presentation caplacizumab(bivalent antibody)